EPHA6
| Official symbol: | EPHA6 |
| Full name: | EPH receptor A6 |
| Location: | 3q11.2 |
| Also known as: | FLJ35246 |
| Entrez ID: | 285220 |
| Ensembl ID: | ENSG00000080224 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.00 |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 8 |
|
|
| Fusions detected in 5 cancer type(s) |
|
| |
|
|
|
| Functional class: | Kinase (protein kinase) |
| JensenLab PubMed score: | 21.83 (Percentile rank: 48.87%) |
| PubTator score: | 11.04 (Percentile rank: 41.77%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets |
| Tractability (antibody): | Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted |
